期刊
HELIYON
卷 6, 期 3, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.heliyon.2020.e03635
关键词
Genetics; Metabolite; Pharmaceutical science; Biochemistry; Epidemiology; Clinical genetics; Laboratory medicine; Clinical research; Lysosomal storage diseases; Colombia; Fabry; Gaucher; Mucopolysaccharidoses
资金
- Pontificia Universidad Javeriana (PPTA) [8275]
- Ministry of Science, Technology and Innovation [120380763212 -PPTA, 8352, 829-2018 PPTA, 8728, 8729]
- Universidad de los Andes
Lysosomal storage diseases (LSDs) are a group of about 50 inborn errors of metabolism characterized by the lysosomal accumulation of partially or non-degraded molecules due to mutations in proteins involved in the degradation of macromolecules, transport, lysosomal biogenesis or modulators of lysosomal environment. Significant advances have been achieved in the diagnosis, management, and treatment of LSDs patients. In terms of approved therapies, these include enzyme replacement therapy (ERT), substrate reduction therapy, hematopoietic stem cell transplantation, and pharmacological chaperone therapy. In this review, we summarize the Colombian experience in LSDs thorough the evidence published. We identified 113 articles published between 1995 and 2019 that included Colombian researchers or physicians, and which were mainly focused in Mucopolysaccharidoses, Pompe disease, Gaucher disease, Fabry disease, and Tay-Sachs and Sandhoff diseases. Most of these articles focused on basic research, clinical cases, and mutation reports. Noteworthy, implementation of the enzyme assay in dried blood samples, led to a 5-fold increase in the identification of LSD patients, suggesting that these disorders still remain undiagnosed in the country. We consider that the information presented in this review will contribute to the knowledge of a broad spectrum of LSDs in Colombia and will also contribute to the development of public policies and the identification of research opportunities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据